The 9th Amsterdam Immunogenicity & Tolerance Seminar will take place on Friday, November 10th from 10:00AM – 6:00PM. All events (including a cocktail networking hour!) will be located at the Hilton Apollolaan in Amsterdam

Register here

About the Amsterdam Immunogenicity & Tolerance Seminar:
Now in its 9th year, the Amsterdam Immunogenicity & Tolerance Seminar has become a much-anticipated forum for sharing research and ideas in the fields of immunogenicity and tolerance.  Academic and industry research has progressed significantly in the past several years, and many advances have been made in the areas of gene therapy, mRNA, CAR-T, and other novel platforms. In addition, traditional protein therapeutics research (still somewhat new as well), has expanded complexity to include Bispecific and Multispecifc antibodies, fusion proteins, and peptide therapeutics. All these exciting developments have generated many questions and added complexity for immunologists, drug developers and medical practitioners working to deliver safe and effective therapies.

Please note, this is an in-person event with no option for virtual attendance. 

2023 speakers are to include:

Annie De Groot, MD


EpiVax Inc.

Prof. Andrew Godkin, MD

Principle Investigator in the Division of Infection and Immunity in Cardiff University

Honorary Consultant Physician in the University Hospital of Wales

Outflanking Viruses and Cancer with CD4+ T Cells – Translating Experimental Findings to Human Studies

Guilhem Richard, PhD

Chief Scientific Officer and Chief Technology Officer

EpiVax Therapeutics

AI-Identification of Self-Like Neoantigens for Developing Enhanced Precision Immunotherapies

Qibo Zhang, MD, PhD

Sr. Lecturer in Immunology

University of Surrey

An in vitro Immune Organoid System for Studying Vaccine-Induced Activation of T Cell and Antibody Responses in Humans

Stephan Gehring, MD

Professor of Pediatrics, Head of Pediatric Intensive Care and Pediatric Infectious Diseases

University Medical Center of Johannes Gutenberg University

Modification of Regulatory T Cell Epitopes Promotes Effector T Cell Responses to a Tumor Antigen

Sally Ward, PhD

Director, Translational Immunology

University of Southampton

Targeting FcRn for the Therapy of Autoimmunity

Sébastien Lacroix-Desmazes, PhD

Director of Research, Immunopathology and Therapeutic Immuno-intervention

Cordeliers Research Center

Transplacental Delivery of Therapeutic Proteins Engineered by IgG

Femke Broere, PhD

Professor of Translational Immunology, Faculty of Veterinary Medicine

Utrecht University

Approach to Therapeutic Tolerance in Rheumatoid Arthritis

Anna Chełmońska-Soyta, PhD

Professor & Laboratory Head, Laboratory of Reproductive Immunology 

Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences

Check out past year’s AIT Seminars:

2022 Amsterdam Immunogenicity & Tolerance Seminar

2021 Amsterdam Immunogenicity & Tolerance Seminar

2019 Amsterdam Immunogenicity & Tolerance Seminar


 Register Now! 


A special thanks to the AIT23 Organizing Committee:

Annie De Groot, MD (CEO/CSO, EpiVax Inc.), Brian Roberts, PhD (Scientific Director, Preclinical Immunology, EpiVax Inc.), Corine Kruiswijk (Director, Translational Research, Intravacc), Christiane Gerke, PhD (Head of Vaccine Programs & Vaccine Innovation Development, Institut Pasteur), Marcel Hoefnagel (Senior Scientist/Assessor, College ter Beoordeling van Geneesmiddelen), and Elly van Riet (Senior Scientist, TuBerculosis Vaccine Initiative)

Questions or suggestions? Contact EpiVax:

COVID-19 Policy: The Westin Immunogenicity Seminar will follow all Japanese COVID-19 guidelines. There will be COVID-19 rapid tests available if you would like to test yourself prior to entering the Seminar. There will also be masks available at arrival.